InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $2.090 0.095 (4.76%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$410 Application for quotation of securities - RAC 28 May 2026 12:07PM $2.650 $2.090 fallen by 21.13%
$410 Appendix 3Y - Dr Daniel Tillett 26 May 2026 1:21PM $2.500 $2.090 fallen by 16.40%
$410 Application for quotation of securities - RAC 26 May 2026 1:18PM $2.500 $2.090 fallen by 16.40%
$410 Appendix 3Y - Dr Daniel Tillett 21 May 2026 1:15PM $2.470 $2.090 fallen by 15.38%
$410 Application for quotation of securities - RAC 21 May 2026 1:12PM $2.470 $2.090 fallen by 15.38%
$410 Racura Oncology Final Option Expiry Reminder 21 May 2026 9:34AM $2.440 $2.090 fallen by 14.34%
$410 CPACS Trial Cleared to Escalate to Next RC220 Dose Level 15 May 2026 9:04AM $2.540 $2.090 fallen by 17.72%
$410 Appendix 3Y - Dr Daniel Tillett 14 May 2026 12:56PM $2.620 $2.090 fallen by 20.23%
$410 Application for quotation of securities - RAC 14 May 2026 12:50PM $2.620 $2.090 fallen by 20.23%
$410 Racura Oncology Options Expiry Reminder 8 May 2026 9:08AM $2.500 $2.090 fallen by 16.40%
$410 Appendix 3Y - Dr Daniel Tillett 7 May 2026 12:10PM $2.470 $2.090 fallen by 15.38%
$410 Application for quotation of securities - RAC 7 May 2026 12:07PM $2.470 $2.090 fallen by 15.38%
$410 Application for quotation of securities - RAC 4 May 2026 1:04PM $2.590 $2.090 fallen by 19.31%
$410 Application for quotation of securities - RAC 30 Apr 2026 1:24PM $2.740 $2.090 fallen by 23.72%
$410 March 2026 Quarterly Activity Report and Appendix 4C 30 Apr 2026 8:50AM $2.640 $2.090 fallen by 20.83%
$410 Racura and Wollongong Uni Granted NSW TechVoucher 29 Apr 2026 9:10AM $2.590 $2.090 fallen by 19.31%
$410 Notification of cessation of securities - RAC 24 Apr 2026 10:40AM $2.900 $2.090 fallen by 27.93%
$410 Application for quotation of securities - RAC 23 Apr 2026 12:42PM $3.020 $2.090 fallen by 30.79%
$410 Racura presents MYC silencing data at AACR 2026 22 Apr 2026 11:13AM $3.160 $2.090 fallen by 33.86%
$410 Application for quotation of securities - RAC 16 Apr 2026 12:21PM $3.020 $2.090 fallen by 30.79%
$410 Racura Singapore and HK Investor Briefing Update 9 Apr 2026 2:54PM $2.730 $2.090 fallen by 23.44%
$410 Application for quotation of securities - RAC 9 Apr 2026 1:33PM $2.810 $2.090 fallen by 25.62%
$410 Appendix 3Y - Dr Daniel Tillett 2 Apr 2026 1:43PM $2.650 $2.090 fallen by 21.13%
$410 Application for quotation of securities - RAC 2 Apr 2026 1:40PM $2.630 $2.090 fallen by 20.53%
$410 First Patient Recruited to HARNESS-1 Lung Cancer Trial 31 Mar 2026 1:53PM $2.360 $2.090 fallen by 11.44%

26 - 50 of 988 results

Page 2 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.